Medical cannabis giant Bod Australia (ASX: BDA) is about to undertake a Phase IIB clinical trial to test the effectiveness of a new CBD medication on insomnia.
Bod will conduct the trial at Australia’s leading sleep and respiratory research organisation: the Woodcock Institute of Medical Research. The trial will include roughly 200 people aged 18 – 65 who have insomnia. In the trial, participants will take a placebo drug and Bod’s new CBD medication in 50mg and 100mg doses. Researchers will then assess the severity of their insomnia using the insomnia severity index. The index specifically analyses whether people have trouble falling asleep, staying asleep, and waking up too early.
Throughout the trial, neither the participants nor the researchers will know which medication participants are on. This will allow researchers to compare the effectiveness of the CBD medication to the placebo drug for eight weeks (though the trial will span 12 weeks in total). The trial will also analyse participant’s anxiety and stress levels.
